Teriparatide

Generic Name: Teriparatide

Brand Names: Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva

Drug Type: Biotech

Chemical Formula: -

CAS Number: 52232-67-4

Unique Ingredient Identifier: 10T9CSU89I

Background: Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...

Indication: Teriparatide is indicated:

Associated Conditions: Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis

Associated Therapies: -

Clinical Trials

Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: teriparatide

First Posted Date: 2007-06-21

Last Posted Date: 2018-07-31

Lead Sponsor: Zosano Pharma Corporation

Target Recruit Count: 165

Registration Number: NCT00489918

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

Phase 2

Terminated

Conditions: Osteoporosis

Interventions: Drug: Alendronate
Drug: Teriparatide
Drug: Ronacaleret

First Posted Date: 2007-05-09

Last Posted Date: 2017-11-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 564

Registration Number: NCT00471237

Locations: 🇪🇸
GSK Investigational Site, Santiago de Compostela, Spain

The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density

Phase 4

Terminated

Conditions: Osteoporosis

Interventions: Drug: teriparatide
Drug: ibandronate

First Posted Date: 2007-03-13

Last Posted Date: 2014-10-29

Lead Sponsor: Papageorgiou General Hospital

Target Recruit Count: 19

Registration Number: NCT00446589

Locations: 🇬🇷
Papageorgiou General Hospital, Thessaloniki, Greece

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Placebo
Drug: Zoledronic acid
Drug: Teriparatide

First Posted Date: 2007-02-23

Last Posted Date: 2011-04-20

Lead Sponsor: Novartis

Target Recruit Count: 412

Registration Number: NCT00439244

Locations: 🇩🇪
Novartis Investigative site, Wuerzburg, Germany
🇪🇸
Novartis Investigative Site, Valencia, Spain

Phase 3 Clinical Trial of Teriparatide in Japan

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Teriparatide
Drug: Placebo

First Posted Date: 2007-02-09

Last Posted Date: 2010-09-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 207

Registration Number: NCT00433160

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tottori, Japan

A Study for Patients With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Teriparatide
Drug: Salmon Calcitonin

First Posted Date: 2006-12-22

Last Posted Date: 2009-10-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 364

Registration Number: NCT00414973

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wenzhou, China

Effects of PTH Replacement on Bone in Hypoparathyroidism

Phase 3

Terminated

Conditions: Hypoparathyroidism
DiGeorge Syndrome

Interventions: Drug: PTH 1-34

First Posted Date: 2006-11-03

Last Posted Date: 2019-08-28

Lead Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)

Target Recruit Count: 46

Registration Number: NCT00395538

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo

Not Applicable

Completed

Conditions: Osteoporosis

Interventions: Drug: Forteo

First Posted Date: 2006-08-18

Last Posted Date: 2009-03-23

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT00365924

Locations: 🇦🇷
Pfizer Investigational Site, Capital Federal - Buenos Aires, Argentina

The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

Not Applicable

Withdrawn

Conditions: Osteoporosis

Interventions: Drug: teriparatide

First Posted Date: 2006-07-04

Last Posted Date: 2013-01-16

Lead Sponsor: Leland Graves III, MD

Registration Number: NCT00347737

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

Phase 3

Completed

Conditions: Back Pain
Spinal Fracture
Osteoporosis, Postmenopausal

Interventions: Drug: teriparatide
Drug: risedronate
Drug: placebo

First Posted Date: 2006-06-22

Last Posted Date: 2011-05-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 712

Registration Number: NCT00343252

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy